Incorporates dedicated storage in Schorndorf for controlled, highly potent or cytotoxic drugs
Catalent Pharma Solutions has completed the expansion of its warehousing facilities in Schorndorf, Germany, announced in January, for its clinical supply services business. This increased capacity for the storage and distribution of Investigational Medicinal Products (IMPs) incorporates dedicated storage for controlled, highly potent or cytotoxic drugs.
The firm has not revealed the investment involved in the project.
The additional storage adds to Catalent’s overall capability and the significant expansion brought about through the acquisition of Aptuit’s Clinical Trial Supplies business completed earlier this year.
Peter Brun, director, Clinical Supply Services, said: ‘The additional GMP storage capacity enhances Catalent’s ability to support customers’ global development and multi-centre clinical studies. Our Schorndorf facility’s central European location is convenient to serve a wide area and assures customers of reliable supply throughout their development programmes and on to commercial supply.’